甲亢一号方联合甲巯咪唑片治疗心肝火盛型毒性弥漫性甲状腺肿临床研究  

Clinical Study on Jiakang No.1 Prescription Combined with Thiamazole Tablets for Patients with Graves'Disease of Vigorous Heart-Liver Fire Type

作　　者：孙丹萍[1] SUN Danping(Shanghai Huangpu District Hospital of Integrated Chinese and Western Medicine,Shanghai 200010,China)

机构地区：[1]上海市黄浦区中西医结合医院,上海200010

出　　处：《新中医》2025年第8期65-69,共5页New Chinese Medicine

基　　金：上海市黄浦区科研项目(HLM202215)。

摘　　要：目的:观察甲亢一号方联合甲巯咪唑片治疗心肝火盛型毒性弥漫性甲状腺肿(Graves病,GD)的临床疗效。方法:选取2022年6月—2024年3月上海市黄浦区中西医结合医院门诊治疗的GD患者60例,按随机数字表法分为治疗组和对照组各30例。治疗组采用甲巯咪唑片联合甲亢一号方治疗,对照组采用甲巯咪唑片口服,治疗3个月,比较2组治疗前后中医证候评分、甲状腺功能指标[血清甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)水平]、促甲状腺激素受体抗体(TRAb)滴度、甲状腺体积及突眼度的变化,并作疗效及安全性判定。结果:治疗后,治疗组总有效率为96.67%(29/30),对照组为93.33%(28/30),2组比较,差异无统计学意义(P>0.05)。治疗后,2组中医证候评分均较治疗前下降(P<0.05),且治疗组中医证候评分低于对照组(P<0.05)。治疗后,2组甲状腺体积均较治疗前缩小(P<0.05);但2组甲状腺体积比较,差异无统计学意义(P>0.05)。治疗后,2组FT3、FT4水平较治疗前降低(P<0.05),TSH水平均较治疗前升高(P<0.05);但2组FT3、FT4、TSH水平比较,差异无统计学意义(P>0.05)。治疗后,2组TRAb滴度水平均较治疗前下降(P<0.05),且治疗组TRAb滴度水平低于对照组(P<0.05)。治疗后,2组左、右突眼度均较治疗前改善(P<0.05),且治疗组左、右突眼度改善优于对照组(P<0.05)。治疗组不良反应发生率为7.14%(2/30),对照组为26.67%(8/30),组间比较,差异有统计学意义(P<0.05)。结论:甲亢一号方联合甲巯咪唑片可以更好地改善心肝火盛型GD病患者的中医证候、甲状腺功能,降低TRAb滴度,缩小甲状腺体积及突眼度,且不良反应较少。Objective:To observe the clinical effect of Jiakang No.1 Prescription combined with Thiamazole Tablets on the treatment of Graves'disease(GD)of vigorous heart-liver fire type.Methods:A total of 60 patients with GD treated at the outpatient clinic of Shanghai Huangpu District Hospital of Integrated Chinese and Western Medicine from June 2022 to March 2024 were selected and randomly divided into the treatment group and the control group according to random number table method,with 30 patients in each group.The treatment group received Thiamazole Tablets combined with Jiakang No.1 Prescription,while the control group received only oral administration of Thiamazole Tablets.After three months of treatment,the changes in traditional Chinese medicine(TCM)syndrome scores,thyroid function indicators[thyroid-stimulating hormone(TSH),free triiodothyronine(FT3),free thyroxine(FT4)],thyroid-stimulating hormone receptor antibody(TRAb)titers,thyroid volume,and exophthalmos degree were compared between the two groups before and after treatment.The effects and safety were also evaluated.Results:After treatment,the total effective rate was 96.67%(29/30)in the treatment group and 93.33%(28/30)in the control group,there being no significant difference between the two groups(P>0.05).After treatment,the TCM syndrome scores in both groups were decreased when compared with those before treatment(P<0.05),and the TCM syndrome scores in the treatment group were lower than those in the control group(P<0.05).After treatment,the thyroid volumes of both groups were decreased when compared with those before treatment(P<0.05),but there was no statistically significant difference in thyroid volume between the two groups(P>0.05).After treatment,the FT3 and FT4 levels in both groups were decreased when compared with those before treatment(P<0.05),while the TSH levels were increased when compared with those before treatment(P<0.05).However,there were no statistically significant differences in FT3,FT4,and TSH levels between the two groups(P>0.05).Af

关 键 词：GRAVES病 心肝火盛 甲亢一号方 甲巯咪唑片 促甲状腺激素受体抗体 突眼度 

分 类 号：R581.1[医药卫生—内分泌]